Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Abstract | Dec 7, 2024

Author

Aldoss I, et al.

Congress

American Society of Hematology Annual Meeting 2024

San Diego, California | Dec 7 – 10, 2024